Search

Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care

BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care

Purchasing

Purchasing at Boehringer Ingelheim

Mental Disorders

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments

Business Ethics

The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.

Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Virtual care pharmacy services offered in Alberta long-term care facilities

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Scam Alert

Monophasic Salmonella Calls for a Comprehensive Vaccination Strategy

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Speak Up

The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.

Equine asthma: Recognizing and managing respiratory issues in horses

Strategies for overcoming resistance in parasites

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner

Philanthropic partnership sets sights on sustainable improvements to health care

Boehringer Ingelheim increases commitments to sustainable development

This World Psoriasis Day, let's learn about generalized pustular psoriasis

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers